MetaCap

MoonLake Immunotherapeutics (MLTX) vs Mentari Therapeutics (MTRI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MoonLake Immunotherapeutics is the larger company by market cap ($942.1 million vs $856.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MLTX-32.29%MTRI+0.68%
+40%-3%-45%
Aug 17, 20261 yearNov 20, 2026
MLTX-29.76%MTRI+0.68%
+31%-6%-43%
Aug 17, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MLTX versus MTRI key metrics
MetricMLTXMTRI
Share price$11.07$14.70
Market cap$942.13M$856.94M
1-day change+0.36%-3.57%
YTD return-16.01%—
1-year return-12.63%—
5-year return+12.16%—
EPS (TTM)$-3.66—
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-227.32M—
52-week high$23.29$23.30
52-week low$9.46$5.75
Distance from 52-week high-52.47%-36.91%
Analyst consensusbuystrong_buy
Avg. price target upside+173.62%—
Average volume1.64M19.42K
Shares outstanding85.11M58.30M
Employees130—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About MoonLake Immunotherapeutics

MLTX stock →

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.

Health Care · Biotechnology: Pharmaceutical Preparations · 130 employees

About Mentari Therapeutics

MTRI stock →

Mentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention. The company's products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing; MT-002, an anti-CGRP; and anti-PACAP bispecific antibody designed to inhibit these complementary pathways.

Health Care · Biotechnology: Pharmaceutical Preparations

MLTX vs MTRI FAQ

Which is bigger, MoonLake Immunotherapeutics or Mentari Therapeutics?

MoonLake Immunotherapeutics (MLTX) is larger, with a market capitalization of $942.13M compared with $856.94M for Mentari Therapeutics (MTRI).

Are MoonLake Immunotherapeutics and Mentari Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons